LARS Fruergaard Jorgensen

0:46:07

LIVE: Reuters Newsmaker with Lars Fruergaard Jørgensen, CEO of Novo Nordisk

2:15:10

Novo Nordisk CEO Lars Jorgensen testifies before Senate on weight loss drugs pricing — 9/24/24

0:49:08

CEO DIALOGUE #35 - Lars Fruergaard Jørgensen, Novo Nordisk

0:13:06

Novo Nordisk CEO on Catalent, Ozempic and Wegovy

0:07:03

Novo Nordisk Raises Forecasts on New Obesity Drug

0:02:01

US healthcare complexities blamed for high drug costs

0:02:53

Ozempic and Wegovy drugmaker CEO defends high costs of drugs

0:04:26

NovoNordisk 'delivers 7% growth,' CEO says despite the impact of Covid

0:04:35

Novo Boosts Profit Outlook on Obesity Drug Demand

0:01:04

Lars Fruergaard Jørgensen

0:04:32

Årets Leder 2020, Lars Fruergaard Jørgensen, CEO i Novo Nordisk

0:04:29

NBC News Exclusive: Ozempic and Wegovy Novo Nordisk CEO speaks out on high prices, drug shortages

0:08:00

Program Cities Changing Diabetes w Polsce: Lars Fruergaard Jorgensen

0:05:37

Novo Nordisk CEO on Earnings, 2020 Outlook, Coronavirus

0:02:48

Novo Nordisk CEO: Very upbeat on outlook for 2022

0:01:00

#BuildBackBetter - Novo Nordisk CEO, Lars Fruergaard Jørgensen

0:06:42

Ozempic CEO grilled on Capitol Hill over high cost of popular weight loss drug

0:01:06

Tomorrow, I will ask the CEO of Novo Nordisk, Mr. Lars Jørgensen:

0:26:50

EFPIA Conference 2024 - What cure to boost EU competitiveness

0:01:51

Very optimistic for 2020, Novo Nordisk CEO says

2:13:50

Ozempic maker testifies about weight loss drug prices during Senate hearing | full video

0:06:17

We Are Positive on Momentum in U.S. Business, Says Novo Nordisk CEO

0:01:31

Årets Erhvervsprofil 2021: Lars Fruergaard Jørgensen

0:24:07

The CEO Behind Ozempic, Wegovy and Europe's Most Valuable Company